Hygiene Labs supports Royal Flying Doctor Service of Australia to prevent the spread of the new Delta variant of COVID-19.

As Australia fights to prevent the spread of the virulent new Delta variant of COVID-19, two of the greatest priorities are to protect the health sector and regional communities. 

The Royal Flying Doctor Service is an integral part of both, providing primary healthcare to those who live and work in rural and remote Australia, as well as to those who visit.

The RFDS operates almost 80 air ambulances nationally, carrying doctors, nurses and dentists to faraway communities, and flying the sick and injured back to cities for critical care.

In an average day, RFDS supports over 1,000 patients, in the air and on the ground, and in a year its aircraft fly more than 27 million kilometres, equivalent to two Sydney-London roundtrips every day.

Since the outbreak of COVID-19, RFDS has intensified its hygiene protocols to maximise protection for patients, medics, air crews, and communities, by introducing the A333 antimicrobial shield treatment, produced by Australian company Hygiene Labs, and delivered by its partner companies, Skygard and 145 Aviation Services.

The air and surface fogging canisters take just six minutes to release within each RFDS aircraft, and the treatment is fully effective within one hour of application.

The Hygiene Labs treatment has been independently verified by global bioanalytical group Eurofins to inactivate surface contamination by Coronavirus and Norovirus for up to 28 days and has been registered by Australia’s Therapeutic Goods Administration as effective for this period of time.

It also has robust aviation credentials, complying with the stringent requirements of major aircraft manufacturers Airbus and Boeing. 

Hygiene Labs is proud to support the Royal Flying Doctor Service of Australia.